Adverse Event Management in HR+/HER2– Advanced Breast Cancer: PI3K/AKT/PTEN Pathway - Episode 3
Overview of the CAPItello-291 Trial
Panelists discuss the findings of the CAPItello-291 trial, which investigated capivasertib combined with fulvestrant in advanced hormone receptor–positive, HER2-negative breast cancer, leading to its approval in November 2023 and highlighting its potential as a new targeted therapy option in the second-line setting due to the prevalence of PIK3CA, AKT1, and PTEN alterations.
Video content above is prompted by the following:
- Dr Huppert: Please summarize the findings of the CAPItello-291 trial investigating capivasertib plus fulvestrant in the advanced hormone receptor–positive, HER2- negative setting, which led to its approval in November 2023. Turner NEJM 2023
- Given the frequency of P13KCA, AKT1, and PTEN alterations, how does capivasertib plus fulvestrant represent a new targeted therapy option in the second-line setting?
- Dr Huppert: What patient factors do you consider when initiating patients on capivasertib?
Related Content:
